IRCT20220813055675N1招募中3 期
Evaluation of the Effects of Ticagrelor on the Prognosis of Percutaneous Coronary Interventions in Patients with Covid-19 and Comparing it with Clopidogrel
Artesh University of Medical Sciences0 个研究点目标入组 200 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 no limit（—）
- 性别
- All
入选标准
- •Patients over 18 years of age who present with acute myocardial infarction.
- •Candidates for emergent coronary angioplasty ( Percutaneous coronary intervention )
- •Less than 24 hours have passed since the onset of chest pain symptoms.
- •are infected with the concomitant covid-19 disease (proved by CT Scan or PCR).
排除标准
- •Lack of patient consent to perform coronary interventions or enter the study
- •Chronic and necessary use of any anti-coagulant drug by the patient
- •severe renal failure (GFR less than 30)
- •Severe heart failure (EF less than 30%)
- •Age under 18 years old
- •Pregnancy or suspected pregnancy
- •History of intracranial or intraspinal bleeding
- •Administration of any intravenous antiviral drug in the same admision
- •Severe liver failure
- •Past history of any malignancy or chemotherapy regimen
研究者
相似试验
招募中
2 期
The short-term outcomes of Ticagrelor versus Clopidogrel in patients with myocardial infarctioAcute myocardial infarction.Other current complications following acute myocardial infarctionI23.8IRCT20180205038626N9Rasht University of Medical Sciences128
进行中（未招募）
1 期
Study of the Effect of Ticagrelor and Clopidogrel on the Immune Response of Healthy VolunteersEUCTR2012-005514-18-GBSheffield Teaching Hospitals NHS Foundation Trust30
招募中
不适用
SETiP-ACS Randomized Clinical TrialKCT0007982Korea University Anam Hospital2,600
招募中
不适用
Ticagrelor monotherapy in PAtients treated with new-generation drug-eluting Stents for acute coronary Syndrome; T-PASS trialDiseases of the circulatory systemKCT0003744Yonsei University Health System, Severance Hospital2,850
招募中
3 期
Ticagrelor Monotherapy vs. DAPT in CCS patients post-PCIIRCT20240701062299N1Shiraz University of Medical Sciences5,400